Lexion Medical, LLC v. Northgate Technologies, Inc.

292 F. App'x 42
CourtCourt of Appeals for the Federal Circuit
DecidedAugust 28, 2008
Docket2007-1420, 2007-1440
StatusUnpublished
Cited by3 cases

This text of 292 F. App'x 42 (Lexion Medical, LLC v. Northgate Technologies, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lexion Medical, LLC v. Northgate Technologies, Inc., 292 F. App'x 42 (Fed. Cir. 2008).

Opinion

SCHALL, Circuit Judge.

DECISION

Defendants-Appellants Northgate Technologies, Inc., Smith & Nephew, Inc., and Linvatec Corp. (“Northgate” or “defendants”) appeal from the final judgment of the United States District Court for the Northern District of Illinois, entered following a jury trial, that Claims 11 and 12 of United States Patent No. 5,411,474 (“the '474 patent”) are valid and were infringed by Northgate. Plaintiff-Cross Appellant Lexion Medical, LLC (“Lexion”) cross-appeals the district court’s determination that Northgate’s post-verdict sales did not constitute willful infringement. It also cross-appeals the district court’s grant of judgment as a matter of law (“JMOL”) that the asserted claims of United States Patent No. 6,068,609 (“the '609 patent”) are invalid for obviousness. We ajfirm-in-patt, vacate-in-patt, and remand for further proceedings.

DISCUSSION

I

During laparoscopic surgery, a small incision is made in the patient’s abdomen, and the abdominal cavity is then inflated with carbon dioxide gas to create an empty space in which a surgeon performs surgery. An important advantage of laparo-scopic surgery is its minimally invasive nature, as it avoids the larger incisions and longer recovery times associated with conventional surgery. A common side effect, however, is that patients often suffer from post-operative shivering and shoulder pain.

Lexion’s '474 and '609 patents disclose and claim a method and apparatus for heating and humidifying the gas used to inflate a patient’s abdomen during laparo-scopic surgery. The heated gas helps reduce the side effects of post-operative shivering and shoulder pain frequently experienced following laparoscopic surgery.

Claim 11 of the '474 patent (with the pertinent limitations underscored) recites the following:

A method of providing heated, humidified gas into a patient for an endoscopic procedure comprising the steps of:

a) directing pressure- and volumetric flow rate-controlled gas, received from an insufflator into a chamber having a means for heating the gas to a temperature within a predetermined range and a means for humidifying the gas and being disposed immediately adjacent to the *45 patient, wherein the chamber is in flow communication with and immediately adjacent to a means for delivering the gas to the interior of the patient;
b) sensing the temperature of the gas as it exits the chamber to determine if it is within the predetermined range; and
c) actuating the heating means if the temperature of the gas is without the predetermined range;
d) humidifying the gas within the chamber; and
e) flowing the gas into the delivering means such that the gas enters the patient humidified and having a temperature within 2°C of the predetermined temperature and thus providing the gas.

Claim 12 of the '474 patent recites:

The method of claim 11, wherein the heating means and the humidifying means heat and humidify the gas simultaneously.

The '609 patent improves upon the '474 patent by including a recharge port on the humidifier that allows the humidifier’s water supply to be replenished during extended surgeries.

II

The Insuflow is Lexion’s commercial embodiment of the patented inventions. The Humi-Flow is the accused device marketed and sold by defendants. 1 Like the inventions which are the subjects of the '474 and '609 patents, the accused Humi-Flow device both heats and humidifies gas inside a chamber before delivering it into a patient’s body for use in laparoscopic surgery. Specifically, the Humi-Flow features a tubular chamber housing a central heater core surrounded by a layer of humidification media. The surface of the humidification media contains grooves which define hollow ducts through which gas flows. As gas flows through these hollow ducts, the heater core and humidification media impart both heat and moisture to the gas. Temperature sensors embedded within the heater core help maintain the temperature of the core at 70°C, by triggering the heater whenever the core temperature falls below 70°C. In this manner, the surrounding gas temperature is indirectly maintained at a temperature between 32-41°C.

Ill

Lexion filed suit against defendants in the United States District Court for the Northern District of Illinois, asserting that their Humi-Flow devices infringed claims 11 and 12 of the '474 patent, and claims 1, 8, 9, 16, and 23 of the '609 patent. Prior to submitting the case to the jury, the district court granted JMOL that the asserted claims of the '609 patent were invalid for obviousness. Thereafter, the jury returned a verdict that claims 11 and 12 of the '474 patent were not invalid and had been literally infringed by the defendants. The jury awarded Lexion $721,662 in damages. 2 Before entry of a permanent injunction, Northgate liquidated its remaining inventory of Humi-Flow devices. In response, Lexion moved to modify the judgment to include enhanced damages for *46 willful infringement. The district court denied the motion, however, electing instead to award compensatory damages for the post-verdict sales, as well as the attorney fees incurred by Lexion in bringing its motion.

IV

Northgate now appeals with respect to the infringement and validity of the '474 patent. Lexion has cross-appealed with respect to willful infringement of the '474 patent and invalidity of the '609 patent. We have jurisdiction over the appeal and the cross-appeal pursuant to 28 U.S.C. § 1295(a)(1).

Claim construction is a question of law which this court reviews de novo. Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1454 (Fed.Cir.1998) (en banc). Literal infringement is a question of fact, reviewed for substantial evidence when tried to a jury. ACCO Brands, Inc. v. ABA Locks Mfrs. Co., 501 F.3d 1307, 1311 (Fed.Cir. 2007). We review a jury’s conclusions on obviousness, a question of law, without deference, and the underlying findings of fact, whether explicit or implicit within the verdict, for substantial evidence. TI Group Automotive Systems (N. Am.), Inc. v. VDO N. Am., LLC, 375 F.3d 1126, 1133 (Fed.Cir.2004). The grant or denial of JMOL is reviewed under the law of the regional circuit in which an appeal from the district court would normally lie. Union Carbide Chems. & Plastics Tech. Corp. v. Shell Oil Co., 425 F.3d 1366, 1372 (Fed. Cir.2005).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lexion Medical, LLC v. Northgate Technologies, Inc.
641 F.3d 1352 (Federal Circuit, 2011)
Trueposition Inc. v. Andrew Corp.
611 F. Supp. 2d 400 (D. Delaware, 2009)
Lexion Medical, LLC v. Northgate Technologies, Inc.
618 F. Supp. 2d 896 (N.D. Illinois, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
292 F. App'x 42, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lexion-medical-llc-v-northgate-technologies-inc-cafc-2008.